Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Construction In Progress : ¥42 Mil (As of Mar. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Shenzhenlubris Pharmaceuticals Co Construction In Progress?

Shenzhenlubris Pharmaceuticals Co's quarterly construction in progress declined from Sep. 2023 (¥78 Mil) to Dec. 2023 (¥34 Mil) but then increased from Dec. 2023 (¥34 Mil) to Mar. 2024 (¥42 Mil).

Shenzhenlubris Pharmaceuticals Co's annual construction in progress declined from Dec. 2021 (¥94 Mil) to Dec. 2022 (¥38 Mil) and declined from Dec. 2022 (¥38 Mil) to Dec. 2023 (¥34 Mil).

Shenzhenlubris Pharmaceuticals Co Construction In Progress Historical Data

The historical data trend for Shenzhenlubris Pharmaceuticals Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhenlubris Pharmaceuticals Co Construction In Progress Chart

Shenzhenlubris Pharmaceuticals Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Construction In Progress

Get a 7-Day Free Trial

206.02

343.78

94.13

37.60

34.35

Shenzhenlubris Pharmaceuticals Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Construction In Progress	Get a 7-Day Free Trial															43.00	59.99	77.82	34.35	42.29

Shenzhenlubris Pharmaceuticals Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 Chuangzhan Center, 6007 Shennan Road, Futian District, Shenzhen, CHN

Website

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalous antibiotics, and bone resorption inhibitors. Its products mainly focused on the areas of cardio-cerebral vascular disease, diabetes, and complications, anti-tumor, and orthopedics, Its business lines include high-end chemical drugs, innovative biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other global countries and regions.

Executives

Yan Jie	Directors, executives
Yang Jian Feng	Secretary, Director
Zhao Song Ping	Executives
Liu Jun	Executives
Li Ai Zhen	Supervisors
Chen Ping	Executives
Ye Cheng Hai	Director
Lu Feng	Executives, directors
Chen Qiong Xing	Supervisors
Li Ying Hui	Supervisors
Pan Ling Man	Independent director
Zhang Zhong Xing	Executives

Shenzhenlubris Pharmaceuticals Co (SZSE:002294) Headlines

No Headlines